Contact Us  |  Site Map  |  Search  |  Client Login  
 
 
Boston Millennia Partners
   
   
  Boston Millennia Partners’ portfolio reflects Millennia’s commitment towards building enduring, large-scale businesses that have the potential to provide superior financial returns to our investors. Millennia’s portfolio is comprised of a diversified group of firms each positioned with the potential to become leaders in their respective market segments. We invite you to use the links below to learn more about each of those portfolio companies.  
     
 
  < Back   
 
 

    Proteome, Inc.
  100 Cummings Center
  Suite 107A
  Beverly, MA 01915

  Phone: 978-922-1643
  Fax: 978 922 3971
 
 
  Proteome, Inc., acquired by Incyte Coporation in 2000, has developed an integrated biological knowledge system to provide researchers with valuable information related to gene and protein function. This platform reduces the complexity of the genomic information landscape by revealing biological connections and relationships across species. Proteome employs its proprietary processes to compile, distill and transform protein information into meaningful biological knowledge. Proteome's database product line, the BioKnowledge Library, consists of multispecies volumes that are interconnected to allow searching between volumes using common protein and gene characteristics. The BioKnowledge Library, available to commercial subscribers, consists of individual volumes (proteome databases) for each model organism, and includes software tools to produce a resource for bioinformatic scientists and biologists of all disciplines.
 
Millennia Team  Rob Jevon
Investment Date  December 1999
Visit the Website  http://www.proteome.com/
Case Study  Proteome / Incyte Genomics provides its customers,
including 20 of the world’s largest pharmaceutical companies, with sophisticated protein analysis database tools that transform scientific publications into an analyzable relational database. Instead of conducting searches of the literature about, e.g. protein interaction, a scientist can access the Proteome database through a link on his or her computer. Users can be assured the data is current because the Proteome staff continually reviews the relevant literature and provides weekly updates to the database. The Proteome services are sold on an annual renewable license basis. Proteome was a pioneer in protein literature curation and developed a formidable head start against potential competitors by virtue of having reviewed and summarized 40,000 scientific articles. The company was sold to Incyte Genomics for cash and stock with an aggregate value of $77 million. We received $16.6 million on our $4.0 million investment. The holding period was 12 months.
Related News 

Palo Alto, CA, - December 29, 2000
Incyte Completes Acquisition of Proteome, Inc.

 
 

 

 
 
  | Our Firm      Our Team      Our Portfolio      Resources      News  
  © 2008 Boston Millennia Partners  All Rights Reserved